Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | RBP4 | P02753 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.51 |
| ▸ | SCD | O00767 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992405 | 0.81 | SCD (0.70) | SCD | |
| SCHEMBL3095680 | 0.78 | HSD11B1 (0.76) | HSD11B1GAARBP4EPHX2TRPV1 | |
| SCHEMBL935839 | 0.78 | SCD (0.77) | SCD | |
| SCHEMBL936764 | 0.77 | KDM4E (0.56) | GAAALDH1A1KMT2ANPSR1SCD | |
| SCHEMBL936939 | 0.77 | SCD (0.63) | SCD | |
| SCHEMBL994567 | 0.77 | ALDH1A1 (0.53) | ALDH1A1MAPK1KMT2ANPSR1 | |
| SCHEMBL27701913 | 0.75 | SCD (0.44) | SCD | |
| SCHEMBL3405262 | 0.75 | SCD (0.49) | SCD | |
| SCHEMBL938314 | 0.75 | SCD (0.56) | SCD | |
| SCHEMBL936676 | 0.75 | SCD (0.49) | SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1804799-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | claimed |
| US-7592343-B2 | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2009-09-22 | — | — | US | claimed |
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | US | claimed |
| EP-1804799-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-07-11 | — | — | EP | claimed |
| WO-2006101521-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-09-28 | — | — | WO | claimed |
| EP-1804799-B1 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | XENON PHARMACEUTICALS INC (CA) | 2013-08-21 | — | — | EP | disclosed |
| US-8026360-B2 | Substituted pyridazines as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2011-09-27 | — | — | US | disclosed |
| EP-2269610-A2 | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors | Xenon Pharmaceuticals Inc. (CA) | 2011-01-05 | — | — | EP | disclosed |
| US-20090306090-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2009-12-10 | — | — | US | disclosed |
| US-7592343-B2 | Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2009-09-22 | — | — | US | disclosed |
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | XENON PHARMACEUTICALS INC. (CA) | 2008-05-29 | — | — | US | disclosed |
| EP-1804799-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006101521-A2 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | XENON PHARMACEUTICALS INC. (CA) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125434-A1 | Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors | SCD, SCD5, NR1H2 | HSD11B1 151/4885GAA 654/4885RBP4 530/4885 |
| US-20090306090-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS | SCD, SCD5, FADS2 | HSD11B1 453/4885GAA 583/4885RBP4 978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.